Search results
Showing 646 to 660 of 1291 results for position
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
A guide to the steps to follow when buying sole supplied titles from Lot 1 of our purchasing framework.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections